Solid Team:Jeff Bluestone, Ph.D., UCSF

Advisor Bluestone

Dr. Jeffrey Bluestone is a member of the scientific advisory board for Solid .

Executive Vice Chancellor/Provost Professor, School of Medicine UCSF.

Jeffrey Bluestone, Ph.D., was appointed executive vice chancellor and provost at the University of California, San Francisco (UCSF) in March 2010, having served in a number of posts including Director, UCSF Diabetes Center and the Immune Tolerance Network, and as interim vice chancellor of research.

As executive vice chancellor and provost, he serves as chief academic officer, guides the research and academic enterprise at UCSF, advances the campus priorities in close collaboration with the chancellor and the campus leadership team, and oversees the campus ethics and compliance enterprise.

As interim vice chancellor—research, Dr. Bluestone directed the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He also worked to strengthen external research partnerships, particularly with the industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

Dr. Bluestone, who holds the A.W. and Mary Margaret Clausen Distinguished Professorship in Metabolism and Endocrinology and is current the director of the Hormone Research Institute, joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center, which focuses on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.